Physician profile
Robert Krzeski
NPI 1871533133
$2,916.18
in general payments reported to CMS, 2019-2025
23 companies · $561 in 2025
The $561 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $110 · 2021: $328 · 2022: $354 · 2023: $673 · 2024: $546 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $466.27 | 2021-2025 | Qelbree, Qelbree |
| Novo Nordisk INC | $411.49 | 2023-2025 | Wegovy |
| Ironshore Pharmaceuticals INC. | $350.95 | 2019-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $329.98 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $241.43 | 2022-2025 | Azstarys |
| Cranial Technologies, INC | $227.30 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $189.09 | 2019-2025 | Bexsero, Arexvy |
| Collegium Pharmaceutical, INC. | $135.71 | 2025 | Jornay Pm |
| Pfizer INC. | $100.34 | 2022-2025 | |
| Kaleo, INC. | $66.56 | 2022-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $56.11 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $50.05 | 2025 | |
| Verrica Pharmaceuticals INC. | $44.27 | 2025 | Ycanth |
| Genentech USA, INC. | $43.95 | 2019 | |
| Tris Pharma INC | $39.42 | 2019-2025 | Dyanavel Xr |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $28.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.66 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.55 | 2024 | Crysvita |
| Sanofi Pasteur INC. | $22.43 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $15.30 | 2025 | Neffy |
| Ironwood Pharmaceuticals, INC | $15.30 | 2024 | |
| Neurelis, INC. | $14.79 | 2025 | Valtoco |
| Neos Therapeutics, LP | $14.48 | 2023 | Cotempla Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Krzeski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.